A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Ashraf Z. Badros, M.D., Ch.B.
Professor of Medicine

Greenebaum Cancer Center
Blood and Marrow Transplantation (BMT)

UMGCC Research Program:
Experimental Therapeutics Program

Medical Degree: Ain Shams University, Cairo, Egypt
Residency: Harbor Hospital Center, Baltimore, Maryland
Fellowship: Georgetown University Medical Center, Medical Oncology and Bone Marrow Transplantation
Roswell Park Cancer Institute, Medical Oncology
Certification: National Boards of Internal Medicine and Medical Oncology

Contact Information:

Mailing Address: UM Greenebaum Cancer Center
22 S. Green Street
Baltimore, MD 21201
Email: abadros@umm.edu
Phone: 410-328-1230

Research Interests:
Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros' research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.

Dr. Badros is involved in the development of targeted novel therapeutics. He has completed a gene therapy trial using G-3039 Bcl-antisense. He evaluated the use of the proteosome inhibitor bortezomib in the newly diagnosed myeloma patients and evaluated the effects of bortezomib on stem cell. Currently, Dr. Badros is evaluating various combinations of novel therapies in multiple myeloma such as Lenalidomide and histone deacetylase inhibitors (SAHA) in relapsed myeloma patients alone and in combinations with dexamethasone and/or bortezomib.

Selected from over 50 peer-reviewed journal articles:

Badros A, Barlogie B, Morris C, et. al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.

Badros A, Barlogie B, Siegel E, et.al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. British Journal of Haematology. 2001:114:600-607.

Badros A, Barlogie B, Siegel E, et.al. Results of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Failure. British Journal of Haematology 2001; 114: 822-829.

Badros A, Tricot G, Toor A, et.al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002; 42: 205-209.

Badros A, Barlogie B, Siegel E, et.al. Improved outcome of Non-myeloablative Allogeneic Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2002; 20: 1295-1303.

Badros AZ, Siegel E, Bodenner D, et.al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. American Journal of Medicine. 2002; 112: 412-413.

Badros AZ, Goloubeva O, Rapoport AP, et.al. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients. J Clin Oncol. 2005 Jun 20;23(18):4089-99. Epub 2005 May 2.

Badros A, Gahres N. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. Clin Adv Hematol Oncol. 2005 Dec;3(12):916-7; discussion 918.

Badros A, Weikel D, Salama A, et.al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb 20; 24(6):945-52.

Badros A, Jaccard A. Bevacizumab Therapy for POEMS Syndrome. Blood. 2006 Jun 15;107 (12):4972-4.

Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 2006 Jun 7 [Epub ahead of print]